NVS EBITDA Growth
Novartis AG Common Stock · EBITDA Growth
NVS EBITDA Growth
Year-over-year change vs the same period a year earlier
Latest reported-1.98%period ending
NVS TTM EBITDA YoY % (130.41% → -1.98%)
Year-over-year change
High-resolution chart · PNG
NVS ebitda growth history
Trailing twelve months (TTM). Each value covers four complete reported quarters.
| Period ending | EBITDA Growth |
|---|---|
| -1.9781% | |
| 2.366% | |
| 10.1653% | |
| 16.3732% | |
| 19.647% | |
| 19.3846% | |
| 13.4758% | |
| 9.6101% | |
| 12.9493% | |
| 12.78% | |
| 14.5448% | |
| -41.4395% | |
| -47.2931% | |
| -50.7321% | |
| -51.7952% | |
| 63.6553% | |
| 74.8875% | |
| 90.7866% | |
| 92.0923% | |
| 12.1257% | |
| 11.1247% | |
| 7.5316% | |
| 10.2139% | |
| 10.129% | |
| 9.2647% | |
| -22.481% | |
| -23.817% | |
| -27.6407% | |
| -29.3924% | |
| 46.5037% | |
| 61.1225% | |
| 77.603% | |
| 82.242% | |
| 9.582% | |
| -13.4499% | |
| -16.9442% | |
| -16.4004% | |
| -7.8919% | |
| 3.0785% | |
| -9.9734% | |
| -17.9724% | |
| -20.6348% | |
| -19.2434% | |
| -8.2618% | |
| 5.6176% | |
| 10.8157% | |
| 10.1285% | |
| 5.9438% | |
| -3.5618% | |
| -5.5713% | |
| -3.6939% | |
| 2.469% | |
| 2.9901% | |
| 2.1964% | |
| -3.8297% | |
| -9.1549% | |
| -5.4889% | |
| 2.3914% | |
| 9.4795% | |
| 10.0705% | |
| 14.8959% | |
| 13.1273% | |
| 23.7905% | |
| 28.1207% | |
| 19.5725% | |
| 12.7727% | |
| -0.545% | |
| 4.8211% | |
| 9.1863% | |
| 17.3982% | |
| 21.9753% | |
| 5.2993% | |
| 6.181% | |
| 1.4497% | |
| 2.8923% | |
| 9.1899% | |
| 6.3987% | |
| 8.4312% | |
| 10.3277% | |
| 14.6505% | |
| 17.3465% | |
| 13.9584% | |
| 9.9704% | |
| 7.8394% | |
| 6.5432% | |
| 11.0437% | |
| 11.0745% | |
| 16.7298% | |
| 19.4514% | |
| 19.6415% | |
| -21.5009% | |
| 452.8975% | |
| 227.4264% | |
| 304.4375% | |
| 718.4433% | |
| -2,488.4615% | |
| 367.9172% | |
| 315.0538% | |
| 130.4094% |